Myomo (MYO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 May, 2026Executive summary
The annual meeting is scheduled for June 25, 2026, and will be held virtually, allowing all shareholders to participate regardless of location.
Shareholders will vote on director elections, executive compensation, auditor ratification, amendments to the stock plan and certificate of incorporation, a shareholder proposal on board classification, and other business.
The board recommends voting for all management proposals except the advisory proposal on board declassification, for which it makes no recommendation.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms: Paul R. Gudonis and Thomas F. Kirk.
Advisory (non-binding) vote on executive compensation (say-on-pay).
Ratification of CBIZ CPAs P.C. as independent auditor for fiscal 2026.
Approval of Amendment No. 3 to the 2018 Stock Option and Incentive Plan, increasing shares by 1,833,000.
Amendment to the certificate of incorporation to increase authorized common shares to 100,000,000.
Advisory shareholder proposal to declassify the board, moving to annual director elections.
Approval of adjournments if needed to solicit additional proxies.
Board of directors and corporate governance
The board consists of six members divided into three staggered classes, with a majority being independent under NYSE American rules.
Board committees include audit, compensation, nominating and corporate governance, and technology, quality and regulatory.
The board held six meetings in 2025, with all directors attending at least 75% of meetings.
The company has a Code of Business Conduct and Ethics and policies on insider trading and hedging.
The board combines the roles of Chairman and CEO, with a lead independent director appointed.
Latest events from Myomo
- Q1 revenue up 3% to $10.1M, gross margin 68.2%, recurring sources now 49% of revenue.MYO
Q1 20268 May 2026 - Expanding reimbursement and clinical validation drive growth, targeting 158M covered lives by 2026.MYO
Investor presentation7 Apr 2026 - Full-year revenue up 26% to $40.9M, with 2026 guidance at $43–$46M and recurring growth focus.MYO
Q4 20259 Mar 2026 - Aims for $100M revenue by 2028, scaling channels, launching new products, and targeting 70%+ margins.MYO
Investor Day 20253 Feb 2026 - Medicare access and O&P channel expansion fuel record growth and a strong 2025 outlook.MYO
24th Annual Needham Virtual Healthcare Conference3 Feb 2026 - Q2 2024 revenue up 77% to $7.5M, with strong pipeline and breakeven targeted for Q4.MYO
Q2 20242 Feb 2026 - Medicare coverage expansion is driving rapid growth and operational scaling for the device.MYO
Small-Cap Growth Virtual Investor Conference1 Feb 2026 - Medicare coverage and operational scale-up fuel record growth and expanded market access.MYO
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Record Q3 revenue, margin gains, and raised guidance highlight accelerating growth.MYO
Q3 202416 Jan 2026